Identification and functional validation of therapeutic targets for malignant melanoma

Critical Reviews in Oncology/Hematology

Volumn 72, Issue 3, 2009, Pages 194-214

  Gremel, Gabriela ^a   Rafferty, Mairin ^a   Lau, Thomas Y K ^a   Gallagher, William M ^a  

^a UNIVERSITY COLLEGE DUBLIN   (Ireland)

Author keywords

Antisense; Functional interrogation; Melanoma; Model systems; RNAi; Targets; Therapy

Indexed keywords

2 (2 METHYL 2 PYRROLIDINYL) 1H BENZIMIDAZOLE 4 CARBOXAMIDE; ANTINEOPLASTIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BEVACIZUMAB; BMS 663513; CARBOPLATIN; CEDIRANIB; CY 503; DACARBAZINE; DASATINIB; DOXORUBICIN; ELESCLOMOL; EVEROLIMUS; IPILIMUMAB; MELPHALAN; MICRORNA; MONOCLONAL ANTIBODY; OBLIMERSEN; OXALIPLATIN; PACLITAXEL; PEGINTERFERON ALPHA2B; PLX 4032; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TICILIMUMAB; TIPIFARNIB; TLN 232; UNCLASSIFIED DRUG; UNINDEXED DRUG;

CANCER MODEL; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; DNA MICROARRAY; DNA SEQUENCE; DRUG MECHANISM; DRUG TARGETING; GENE EXPRESSION PROFILING; HUMAN; IN VITRO STUDY; MELANOMA; NONHUMAN; PROTEIN TARGETING; REVIEW; RNA INTERFERENCE; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSGENIC ANIMAL; TUMOR BIOPSY; TUMOR XENOGRAFT;

ANIMALS; GENE EXPRESSION PROFILING; HUMANS; MELANOMA; MODELS, BIOLOGICAL; SKIN NEOPLASMS;

EID: 71549144773     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.critrevonc.2009.02.004     Document Type: Review

References (192)

1. Marquette A., Bagot M., Bensussan A., and Dumaz N. Recent discoveries in the genetics of melanoma and their therapeutic implications. Arch Immunol Ther Exp (Warsz) 55 (2007) 363-372
2. Lens M. Current clinical overview of cutaneous melanoma. Br J Nurs 17 (2008) 300-305
3. Beddingfield III F.C. The melanoma epidemic: res ipsa loquitur. Oncologist 8 (2003) 459-465
4. Tsao H., Atkins M.B., and Sober A.J. Management of cutaneous melanoma. N Engl J Med 351 (2004) 998-1012
5. Kirkwood J.M., Ibrahim J.G., Sosman J.A., et al. High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801. J Clin Oncol 19 (2001) 2370-2380
6. Kirkwood J.M., Strawderman M.H., Ernstoff M.S., Smith T.J., Borden E.C., and Blum R.H. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 14 (1996) 7-17
7. Sasse A.D., Sasse E.C., Clark L.G., Ulloa L., and Clark O.A. Chemoimmunotherapy versus chemotherapy for metastatic malignant melanoma. Cochrane Database Syst Rev (2007) CD005413
8. Clark S.R., and Sidebottom E. Selection of metastatic variants on the basis of clonal morphology in vitro. Invasion Metastasis 4, Suppl. 1 (1984) 1-11
9. Chin L., Merlino G., and DePinho R.A. Malignant melanoma: modern black plague and genetic black box. Genes Dev 12 (1998) 3467-3481
10. Troiani T., Schettino C., Martinelli E., Morgillo F., Tortora G., and Ciardiello F. The use of xenograft models for the selection of cancer treatments with the EGFR as an example. Crit Rev Oncol Hematol 65 (2008) 200-211
11. Oosterhuis J.W., Coebergh J.W., and van Veen E.B. Tumour banks: well-guarded treasures in the interest of patients. Nat Rev Cancer 3 (2003) 73-77
12. Cambon-Thomsen A. The social and ethical issues of post-genomic human biobanks. Nat Rev Genet 5 (2004) 866-873
13. Morente M.M., and Alonso S. Current challenges of human tumour banking. Hematol Oncol 23 (2005) 54-56
14. Friedrich J., Ebner R., and Kunz-Schughart L.A. Experimental anti-tumor therapy in 3-D: spheroids--old hat or new challenge?. Int J Radiat Biol 83 (2007) 849-871
15. Lee J.T., and Herlyn M. Microenvironmental influences in melanoma progression. J Cell Biochem 101 (2007) 862-872
16. Khavari P.A. Modelling cancer in human skin tissue. Nat Rev Cancer 6 (2006) 270-280
17. Larue L., and Beermann F. Cutaneous melanoma in genetically modified animals. Pigment Cell Res 20 (2007) 485-497
18. Thompson F.H., Emerson J., Olson S., et al. Cytogenetics of 158 patients with regional or disseminated melanoma. Subset analysis of near-diploid and simple karyotypes. Cancer Genet Cytogenet 83 (1995) 93-104
19. Nelson M.A., Thompson F.H., Emerson J., et al. Clinical implications of cytogenetic abnormalities in melanoma. Surg Clin North Am 76 (1996) 1257-1271
20. Hoefig K.P., Thorns C., Roehle A., et al. Unlocking pathology archives for microRNA-profiling. Anticancer Res 28 (2008) 119-123
21. Li J., Smyth P., Flavin R., et al. Comparison of miRNA expression patterns using total RNA extracted from matched samples of formalin-fixed paraffin-embedded (FFPE) cells and snap frozen cells. BMC Biotechnol 7 (2007) 36
22. Nuovo G.J. In situ detection of precursor and mature microRNAs in paraffin embedded, formalin fixed tissues and cell preparations. Methods 44 (2008) 39-46
23. Szafranska A.E., Davison T.S., Shingara J., et al. Accurate molecular characterization of formalin-fixed, paraffin-embedded tissues by microRNA expression profiling. J Mol Diagn 10 (2008) 411-414
24. Winnepenninckx V., Lazar V., Michiels S., et al. Gene expression profiling of primary cutaneous melanoma and clinical outcome. J Natl Cancer Inst 98 (2006) 472-482
25. Lin W.M., Baker A.C., Beroukhim R., et al. Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res 68 (2008) 664-673
26. Ryu B., Kim D.S., Deluca A.M., and Alani R.M. Comprehensive expression profiling of tumor cell lines identifies molecular signatures of melanoma progression. PLoS ONE 2 (2007) e594
27. Hoek K.S. DNA microarray analyses of melanoma gene expression: a decade in the mines. Pigment Cell Res 20 (2007) 466-484
28. Hsu M.Y. The Wistar melanoma (WM) cell lines. Human cell culture (2002), Springer, Netherlands p. 259-74
29. Jacob K., Bosserhoff A.K., Wach F., et al. Characterization of selected strongly and weakly invasive sublines of a primary human melanoma cell line and isolation of subtractive cDNA clones. Int J Cancer 60 (1995) 668-675
30. Poste G., Doll J., Hart I.R., and Fidler I.J. In vitro selection of murine B16 melanoma variants with enhanced tissue-invasive properties. Cancer Res 40 (1980) 1636-1644
31. Fidler I.J. Selection of successive tumour lines for metastasis. Nat New Biol 242 (1973) 148-149
32. Poste G., and Fidler I.J. The pathogenesis of cancer metastasis. Nature 283 (1980) 139-146
33. Hatina J., and Ruzicka T. Relevance of cell culture models in cutaneous tumour biology: Part I: Tumour cell lines. Hautarzt 59 (2008) 36-45
34. Ross D.T., Scherf U., Eisen M.B., et al. Systematic variation in gene expression patterns in human cancer cell lines. Nat Genet 24 (2000) 227-235
35. Valyi-Nagy I.T., Hirka G., Jensen P.J., Shih I.M., Juhasz I., and Herlyn M. Undifferentiated keratinocytes control growth, morphology, and antigen expression of normal melanocytes through cell-cell contact. Lab Invest 69 (1993) 152-159
36. Shih I.M., Elder D.E., Hsu M.Y., and Herlyn M. Regulation of Mel-CAM/MUC18 expression on melanocytes of different stages of tumor progression by normal keratinocytes. Am J Pathol 145 (1994) 837-845
37. Fukunaga-Kalabis M., Martinez G., Liu Z.J., et al. CCN3 controls 3D spatial localization of melanocytes in the human skin through DDR1. J Cell Biol 175 (2006) 563-569
38. Fukunaga-Kalabis M., Martinez G., Telson S.M., et al. Downregulation of CCN3 expression as a potential mechanism for melanoma progression. Oncogene 27 (2008) 2552-2560
39. Hsu M.Y., Shih D.T., Meier F.E., et al. Adenoviral gene transfer of beta3 integrin subunit induces conversion from radial to vertical growth phase in primary human melanoma. Am J Pathol 153 (1998) 1435-1442
40. Meier F., Nesbit M., Hsu M.Y., et al. Human melanoma progression in skin reconstructs: biological significance of bFGF. Am J Pathol 156 (2000) 193-200
41. Lo R.S., and Witte O.N. Transforming growth factor-beta activation promotes genetic context-dependent invasion of immortalized melanocytes. Cancer Res 68 (2008) 4248-4257
42. Ghosh S., Spagnoli G.C., Martin I., et al. Three-dimensional culture of melanoma cells profoundly affects gene expression profile: a high density oligonucleotide array study. J Cell Physiol 204 (2005) 522-531
43. Ghosh S., Joshi M.B., Ivanov D., et al. Use of multicellular tumor spheroids to dissect endothelial cell-tumor cell interactions: a role for T-cadherin in tumor angiogenesis. FEBS Lett 581 (2007) 4523-4528
44. Smalley K.S., Haass N.K., Brafford P.A., Lioni M., Flaherty K.T., and Herlyn M. Multiple signaling pathways must be targeted to overcome drug resistance in cell lines derived from melanoma metastases. Mol Cancer Ther 5 (2006) 1136-1144
45. Smalley K.S., Contractor R., Nguyen T.K., et al. Identification of a novel subgroup of melanomas with KIT/cyclin-dependent kinase-4 overexpression. Cancer Res 68 (2008) 5743-5752
46. Smalley K.S., Brafford P.A., and Herlyn M. Selective evolutionary pressure from the tissue microenvironment drives tumor progression. Semin Cancer Biol 15 (2005) 451-459
47. Kankuri E., Cholujova D., Comajova M., Vaheri A., and Bizik J. Induction of hepatocyte growth factor/scatter factor by fibroblast clustering directly promotes tumor cell invasiveness. Cancer Res 65 (2005) 9914-9922
48. Prada F., Benedetti L.G., Bravo A.I., Alvarez M.J., Carbone C., and Podhajcer O.L. SPARC endogenous level, rather than fibroblast-produced SPARC or stroma reorganization induced by SPARC, is responsible for melanoma cell growth. J Invest Dermatol 127 (2007) 2618-2628
49. Kloss D., Kurz R., Jahnke H.G., et al. Microcavity array (MCA)-based biosensor chip for functional drug screening of 3D tissue models. Biosens Bioelectron 23 (2008) 1473-1480
50. Javelaud D., Mohammad K.S., McKenna C.R., et al. Stable overexpression of Smad7 in human melanoma cells impairs bone metastasis. Cancer Res 67 (2007) 2317-2324
51. Arguello F., Baggs R.B., and Frantz C.N. A murine model of experimental metastasis to bone and bone marrow. Cancer Res 48 (1988) 6876-6881
52. Rosol T.J., Tannehill-Gregg S.H., Corn S., Schneider A., and McCauley L.K. Animal models of bone metastasis. Cancer Treat Res 118 (2004) 47-81
53. Deroose C.M., De A., Loening A.M., et al. Multimodality imaging of tumor xenografts and metastases in mice with combined small-animal PET, small-animal CT, and bioluminescence imaging. J Nucl Med 48 (2007) 295-303
54. Ray P., Tsien R., and Gambhir S.S. Construction and validation of improved triple fusion reporter gene vectors for molecular imaging of living subjects. Cancer Res 67 (2007) 3085-3093
55. Soballe P.W., Montone K.T., Satyamoorthy K., Nesbit M., and Herlyn M. Carcinogenesis in human skin grafted to SCID mice. Cancer Res 56 (1996) 757-764
56. Juhasz I., Albelda S.M., Elder D.E., et al. Growth and invasion of human melanomas in human skin grafted to immunodeficient mice. Am J Pathol 143 (1993) 528-537
57. Lazarov M., Kubo Y., Cai T., et al. CDK4 coexpression with Ras generates malignant human epidermal tumorigenesis. Nat Med 8 (2002) 1105-1114
58. Dajee M., Lazarov M., Zhang J.Y., et al. NF-kappaB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 421 (2003) 639-643
59. Chudnovsky Y., Adams A.E., Robbins P.B., Lin Q., and Khavari P.A. Use of human tissue to assess the oncogenic activity of melanoma-associated mutations. Nat Genet 37 (2005) 745-749
60. Benjamin C.L., Melnikova V.O., and Ananthaswamy H.N. Models and mechanisms in malignant melanoma. Mol Carcinog 46 (2007) 671-678
61. Inoue-Narita T., Hamada K., Sasaki T., et al. Pten deficiency in melanocytes results in resistance to hair graying and susceptibility to carcinogen-induced melanomagenesis. Cancer Res 68 (2008) 5760-5768
62. Stoletov K., and Klemke R. Catch of the day: zebrafish as a human cancer model. Oncogene 27 (2008) 4509-4520
63. Patton E.E., Widlund H.R., Kutok J.L., et al. BRAF mutations are sufficient to promote nevi formation and cooperate with p53 in the genesis of melanoma. Curr Biol 15 (2005) 249-254
64. White R.M., Sessa A., Burke C., et al. Transparent adult zebrafish as a tool for in vivo transplantation analysis. Cell Stem Cell 2 (2008) 183-189
65. Kunz M., Ibrahim S.M., Koczan D., Scheid S., Thiesen H.J., and Gross G. DNA microarray technology and its applications in dermatology. Exp Dermatol 13 (2004) 593-606
66. Bauer J., and Bastian B.C. Distinguishing melanocytic nevi from melanoma by DNA copy number changes: comparative genomic hybridization as a research and diagnostic tool. Dermatol Ther 19 (2006) 40-49
67. Bignell G.R., Huang J., Greshock J., et al. High-resolution analysis of DNA copy number using oligonucleotide microarrays. Genome Res 14 (2004) 287-295
68. Bernard K., Litman E., Fitzpatrick J.L., et al. Functional proteomic analysis of melanoma progression. Cancer Res 63 (2003) 6716-6725
69. de Souza G.A., Godoy L.M., Teixeira V.R., et al. Proteomic and SAGE profiling of murine melanoma progression indicates the reduction of proteins responsible for ROS degradation. Proteomics 6 (2006) 1460-1470
70. Carta F., Demuro P.P., Zanini C., et al. Analysis of candidate genes through a proteomics-based approach in primary cell lines from malignant melanomas and their metastases. Melanoma Res 15 (2005) 235-244
71. Al-Ghoul M., Bruck T.B., Lauer-Fields J.L., et al. Comparative proteomic analysis of matched primary and metastatic melanoma cell lines. J Proteome Res 7 (2008) 4107-4118
72. Dai D.L., Wang Y., Liu M., Martinka M., and Li G. Bim expression is reduced in human cutaneous melanomas. J Invest Dermatol 128 (2008) 403-407
73. Bubendorf L., Nocito A., Moch H., and Sauter G. Tissue microarray (TMA) technology: miniaturized pathology archives for high-throughput in situ studies. J Pathol 195 (2001) 72-79
74. Li J., Martinka M., and Li G. Role of ING4 in human melanoma cell migration, invasion and patient survival. Carcinogenesis 29 (2008) 1373-1379
75. Rangel J., Nosrati M., Leong S.P., et al. Novel role for RGS1 in melanoma progression. Am J Surg Pathol 32 (2008) 1207-1212
76. Kononen J., Bubendorf L., Kallioniemi A., et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 4 (1998) 844-847
77. Schultz J., Lorenz P., Gross G., Ibrahim S., and Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 18 (2008) 549-557
78. Muller D.W., and Bosserhoff A.K. Integrin beta(3) expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 27 (2008) 6698-6706
79. Felicetti F., Errico M.C., Bottero L., et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 68 (2008) 2745-2754
80. Sellheyer K., and Belbin T.J. DNA microarrays: from structural genomics to functional genomics. The applications of gene chips in dermatology and dermatopathology. J Am Acad Dermatol 51 (2004) 681-692 [quiz 93-6]
81. Allison D.B., Cui X., Page G.P., and Sabripour M. Microarray data analysis: from disarray to consolidation and consensus. Nat Rev Genet 7 (2006) 55-65
82. Nambiar S., Mirmohammadsadegh A., and Hengge U.R. Cutaneous melanoma: fishing with chips. Curr Mol Med 8 (2008) 235-243
83. Clark E.A., Golub T.R., Lander E.S., and Hynes R.O. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 406 (2000) 532-535
84. DeRisi J., Penland L., Brown P.O., et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 14 (1996) 457-460
85. Gallagher W.M., Bergin O.E., Rafferty M., et al. Multiple markers for melanoma progression regulated by DNA methylation: insights from transcriptomic studies. Carcinogenesis 26 (2005) 1856-1867
86. Gutgemann A., Golob M., Muller S., Buettner R., and Bosserhoff A.K. Isolation of invasion-associated cDNAs in melanoma. Arch Dermatol Res 293 (2001) 283-290
87. Rumpler G., Becker B., Hafner C., et al. Identification of differentially expressed genes in models of melanoma progression by cDNA array analysis: SPARC, MIF and a novel cathepsin protease characterize aggressive phenotypes. Exp Dermatol 12 (2003) 761-771
88. Su Y.A., Bittner M.L., Chen Y., et al. Identification of tumor-suppressor genes using human melanoma cell lines UACC903, UACC903(+6), and SRS3 by comparison of expression profiles. Mol Carcinog 28 (2000) 119-127
89. Bittner M., Meltzer P., Chen Y., et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 406 (2000) 536-540
90. Haqq C., Nosrati M., Sudilovsky D., et al. The gene expression signatures of melanoma progression. Proc Natl Acad Sci U S A 102 (2005) 6092-6097
91. Smith A.P., Hoek K., and Becker D. Whole-genome expression profiling of the melanoma progression pathway reveals marked molecular differences between nevi/melanoma in situ and advanced-stage melanomas. Cancer Biol Ther 4 (2005) 1018-1029
92. Jaeger J., Koczan D., Thiesen H.J., et al. Gene expression signatures for tumor progression, tumor subtype, and tumor thickness in laser-microdissected melanoma tissues. Clin Cancer Res 13 (2007) 806-815
93. Riker A.I., Enkemann S.A., Fodstad O., et al. The gene expression profiles of primary and metastatic melanoma yields a transition point of tumor progression and metastasis. BMC Med Genomics 1 (2008) 13
94. Alonso S.R., Tracey L., Ortiz P., et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res 67 (2007) 3450-3460
95. John T., Black M.A., Toro T.T., et al. Predicting clinical outcome through molecular profiling in stage III melanoma. Clin Cancer Res 14 (2008) 5173-5180
96. Eulalio A., Huntzinger E., and Izaurralde E. Getting to the root of miRNA-mediated gene silencing. Cell 132 (2008) 9-14
97. Bushati N., and Cohen S.M. microRNA functions. Annu Rev Cell Dev Biol 23 (2007) 175-205
98. Blenkiron C., Goldstein L.D., Thorne N.P., et al. MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype. Genome Biol 8 (2007) R214
99. Ambs S., Prueitt R.L., Yi M., et al. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res 68 (2008) 6162-6170
100. Bastian B.C., Olshen A.B., LeBoit P.E., and Pinkel D. Classifying melanocytic tumors based on DNA copy number changes. Am J Pathol 163 (2003) 1765-1770
101. Zhang L., Huang J., Yang N., et al. microRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 103 (2006) 9136-9141
102. Curtin J.A., Fridlyand J., Kageshita T., et al. Distinct sets of genetic alterations in melanoma. N Engl J Med 353 (2005) 2135-2147
103. Garraway L.A., Widlund H.R., Rubin M.A., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 436 (2005) 117-122
104. Thomas R.K., Baker A.C., Debiasi R.M., et al. High-throughput oncogene mutation profiling in human cancer. Nat Genet 39 (2007) 347-351
105. Wu H., Goel V., and Haluska F.G. PTEN signaling pathways in melanoma. Oncogene 22 (2003) 3113-3122
106. de Godoy L.M., Olsen J.V., Cox J., et al. Comprehensive mass-spectrometry-based proteome quantification of haploid versus diploid yeast. Nature 455 (2008) 1251-1254
107. Culp W.D., Neal R., Massey R., Egevad L., Pisa P., and Garland D. Proteomic analysis of tumor establishment and growth in the B16-F10 mouse melanoma model. J Proteome Res 5 (2006) 1332-1343
108. Zuidervaart W., Hensbergen P.J., Wong M.C., et al. Proteomic analysis of uveal melanoma reveals novel potential markers involved in tumor progression. Invest Ophthalmol Vis Sci 47 (2006) 786-793
109. Rivera J., Megias D., and Bravo J. Proteomics-based strategy to delineate the molecular mechanisms of the metastasis suppressor gene BRMS1. J Proteome Res 6 (2007) 4006-4018
110. Stockwin L.H., Blonder J., Bumke M.A., et al. Proteomic analysis of plasma membrane from hypoxia-adapted malignant melanoma. J Proteome Res 5 (2006) 2996-3007
111. Craven R.A., Stanley A.J., Hanrahan S., et al. Identification of proteins regulated by interferon-alpha in resistant and sensitive malignant melanoma cell lines. Proteomics 4 (2004) 3998-4009
112. Pardo M., Garcia A., Antrobus R., Blanco M.J., Dwek R.A., and Zitzmann N. Biomarker discovery from uveal melanoma secretomes: identification of gp100 and cathepsin D in patient serum. J Proteome Res 6 (2007) 2802-2811
113. Qiu H., and Wang Y. Quantitative analysis of surface plasma membrane proteins of primary and metastatic melanoma cells. J Proteome Res 7 (2008) 1904-1915
114. Baruthio F., Quadroni M., Ruegg C., and Mariotti A. Proteomic analysis of membrane rafts of melanoma cells identifies protein patterns characteristic of the tumor progression stage. Proteomics 8 (2008) 4733-4747
115. Service R.F. Proteomics. Will biomarkers take off at last?. Science 321 (2008) 1760
116. Baggerly K.A., Morris J.S., and Coombes K.R. Reproducibility of SELDI-TOF protein patterns in serum: comparing datasets from different experiments. Bioinformatics 20 (2004) 777-785
117. Mian S., Ugurel S., Parkinson E., et al. Serum proteomic fingerprinting discriminates between clinical stages and predicts disease progression in melanoma patients. J Clin Oncol 23 (2005) 5088-5093
118. Rezaul K., Wilson L.L., and Han D.K. Direct tissue proteomics in human diseases: potential applications to melanoma research. Expert Rev Proteomics 5 (2008) 405-412
119. Hanash S.M., Pitteri S.J., and Faca V.M. Mining the plasma proteome for cancer biomarkers. Nature 452 (2008) 571-579
120. Giltnane J.M., and Rimm D.L. Technology insight: identification of biomarkers with tissue microarray technology. Nat Clin Pract Oncol 1 (2004) 104-111
121. Kallioniemi O.P., Wagner U., Kononen J., and Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10 (2001) 657-662
122. Alonso S.R., Ortiz P., Pollan M., et al. Progression in cutaneous malignant melanoma is associated with distinct expression profiles: a tissue microarray-based study. Am J Pathol 164 (2004) 193-203
123. Berger A.J., Kluger H.M., Li N., et al. Subcellular localization of activating transcription factor 2 in melanoma specimens predicts patient survival. Cancer Res 63 (2003) 8103-8107
124. Pacifico M.D., Grover R., Richman P., Daley F., and Wilson G.D. Validation of tissue microarray for the immunohistochemical profiling of melanoma. Melanoma Res 14 (2004) 39-42
125. Berger A.J., Camp R.L., Divito K.A., Kluger H.M., Halaban R., and Rimm D.L. Automated quantitative analysis of HDM2 expression in malignant melanoma shows association with early-stage disease and improved outcome. Cancer Res 64 (2004) 8767-8772
126. Divito K.A., Berger A.J., Camp R.L., Dolled-Filhart M., Rimm D.L., and Kluger H.M. Automated quantitative analysis of tissue microarrays reveals an association between high Bcl-2 expression and improved outcome in melanoma. Cancer Res 64 (2004) 8773-8777
127. McCarthy M.M., Pick E., Kluger Y., et al. HSP90 as a marker of progression in melanoma. Ann Oncol 19 (2008) 590-594
128. Boutros M., and Ahringer J. The art and design of genetic screens: RNA interference. Nat Rev Genet 9 (2008) 554-566
129. Lindsay M.A. Target discovery. Nat Rev Drug Discov 2 (2003) 831-838
130. Corey D.R. RNA learns from antisense. Nat Chem Biol 3 (2007) 8-11
131. Gleave M.E., and Monia B.P. Antisense therapy for cancer. Nat Rev Cancer 5 (2005) 468-479
132. Bedikian A.Y., Millward M., Pehamberger H., et al. Bcl-2 antisense (oblimersen sodium) plus dacarbazine in patients with advanced melanoma: the Oblimersen Melanoma Study Group. J Clin Oncol 24 (2006) 4738-4745
133. Rana T.M. Illuminating the silence: understanding the structure and function of small RNAs. Nat Rev Mol Cell Biol 8 (2007) 23-36
134. Rossi J.J. Expression strategies for short hairpin RNA interference triggers. Hum Gene Ther 19 (2008) 313-317
135. Hannon G.J., and Rossi J.J. Unlocking the potential of the human genome with RNA interference. Nature 431 (2004) 371-378
136. Holen T. Efficient prediction of siRNAs with siRNArules 1.0: an open-source JAVA approach to siRNA algorithms. RNA 12 (2006) 1620-1625
137. Jia P., Shi T., Cai Y., and Li Y. Demonstration of two novel methods for predicting functional siRNA efficiency. BMC Bioinform 7 (2006) 271
138. Koberle C., Kaufmann S.H., and Patzel V. Selecting effective siRNAs based on guide RNA structure. Nat Protoc 1 (2006) 1832-1839
139. Reynolds A., Leake D., Boese Q., Scaringe S., Marshall W.S., and Khvorova A. Rational siRNA design for RNA interference. Nat Biotechnol 22 (2004) 326-330
140. Juliano R., Alam M.R., Dixit V., and Kang H. Mechanisms and strategies for effective delivery of antisense and siRNA oligonucleotides. Nucleic Acids Res 36 (2008) 4158-4171
141. Li S.D., Chono S., and Huang L. Efficient oncogene silencing and metastasis inhibition via systemic delivery of siRNA. Mol Ther 16 (2008) 942-946
142. Akhtar S., and Benter I.F. Nonviral delivery of synthetic siRNAs in vivo. J Clin Invest 117 (2007) 3623-3632
143. Kim D.H., and Rossi J.J. Strategies for silencing human disease using RNA interference. Nat Rev Genet 8 (2007) 173-184
144. Kumar L.D., and Clarke A.R. Gene manipulation through the use of small interfering RNA (siRNA): from in vitro to in vivo applications. Adv Drug Deliv Rev 59 (2007) 87-100
145. Dunlap S., Yu X., Cheng L., Civin C.I., and Alani R.M. High-efficiency stable gene transduction in primary human melanocytes using a lentiviral expression system. J Invest Dermatol 122 (2004) 549-551
146. Esquela-Kerscher A., and Slack F.J. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6 (2006) 259-269
147. Worley L.A., Long M.D., Onken M.D., and Harbour J.W. Micro-RNAs associated with metastasis in uveal melanoma identified by multiplexed microarray profiling. Melanoma Res 18 (2008) 184-190
148. Weiler J., Hunziker J., and Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?. Gene Ther 13 (2006) 496-502
149. Krutzfeldt J., Rajewsky N., Braich R., et al. Silencing of microRNAs in vivo with 'antagomirs'. Nature 438 (2005) 685-689
150. Imai K., and Takaoka A. Comparing antibody and small-molecule therapies for cancer. Nat Rev Cancer 6 (2006) 714-727
151. Evelyn C.R., Wade S.M., Wang Q., et al. CCG-1423: a small-molecule inhibitor of RhoA transcriptional signaling. Mol Cancer Ther 6 (2007) 2249-2260
152. Ma Y., Kurtyka C.A., Boyapalle S., et al. A small-molecule E2F inhibitor blocks growth in a melanoma culture model. Cancer Res 68 (2008) 6292-6299
153. Rowlands M.G., Newbatt Y.M., Prodromou C., Pearl L.H., Workman P., and Aherne W. High-throughput screening assay for inhibitors of heat-shock protein 90 ATPase activity. Anal Biochem 327 (2004) 176-183
154. Jones D.T., and Harris A.L. Identification of novel small-molecule inhibitors of hypoxia-inducible factor-1 transactivation and DNA binding. Mol Cancer Ther 5 (2006) 2193-2202
155. Druker B.J. Imatinib as a paradigm of targeted therapies. Adv Cancer Res 91 (2004) 1-30
156. Kim K.B., Eton O., Davis D.W., et al. Phase II trial of imatinib mesylate in patients with metastatic melanoma. Br J Cancer 99 (2008) 734-740
157. Haass N.K., Sproesser K., Nguyen T.K., et al. The Mitogen-activated protein/extracellular signal-regulated kinase inhibitor AZD6244 (ARRY-142886) induces growth arrest in melanoma cells and tumor regression when combined with docetaxel. Clin Cancer Res 14 (2008) 230-239
158. Sharp S.Y., Boxall K., Rowlands M., et al. In vitro biological characterization of a novel, synthetic diaryl pyrazole resorcinol class of heat shock protein 90 inhibitors. Cancer Res 67 (2007) 2206-2216
159. Puri N., Ahmed S., Janamanchi V., et al. c-Met is a potentially new therapeutic target for treatment of human melanoma. Clin Cancer Res 13 (2007) 2246-2253
160. Alexaki V.I., Javelaud D., and Mauviel A. JNK supports survival in melanoma cells by controlling cell cycle arrest and apoptosis. Pigment Cell Melanoma Res 21 (2008) 429-438
161. Reschke M., Mihic-Probst D., van der Horst E.H., et al. HER3 is a determinant for poor prognosis in melanoma. Clin Cancer Res 14 (2008) 5188-5197
162. Ricke D.O., Wang S., Cai R., and Cohen D. Genomic approaches to drug discovery. Curr Opin Chem Biol 10 (2006) 303-308
163. Arias A.M. Drosophila melanogaster and the development of biology in the 20th century. Methods Mol Biol 420 (2008) 1-25
164. Lee J., Nam S., Hwang S.B., et al. Functional genomic approaches using the nematode Caenorhabditis elegans as a model system. J Biochem Mol Biol 37 (2004) 107-113
165. Bailey S.N., Ali S.M., Carpenter A.E., Higgins C.O., and Sabatini D.M. Microarrays of lentiviruses for gene function screens in immortalized and primary cells. Nat Methods 3 (2006) 117-122
166. Bernards R., Brummelkamp T.R., and Beijersbergen R.L. shRNA libraries and their use in cancer genetics. Nat Methods 3 (2006) 701-706
167. Kassner P.D. Discovery of novel targets with high throughput RNA interference screening. Comb Chem High Throughput Screen 11 (2008) 175-184
168. Gumireddy K., Sun F., Klein-Szanto A.J., et al. In vivo selection for metastasis promoting genes in the mouse. Proc Natl Acad Sci U S A 104 (2007) 6696-6701
169. Whitehurst A.W., Bodemann B.O., Cardenas J., et al. Synthetic lethal screen identification of chemosensitizer loci in cancer cells. Nature 446 (2007) 815-819
170. Giuliano K.A., Haskins J.R., and Taylor D.L. Advances in high content screening for drug discovery. Assay Drug Dev Technol 1 (2003) 565-577
171. Korn K., and Krausz E. Cell-based high-content screening of small-molecule libraries. Curr Opin Chem Biol 11 (2007) 503-510
172. Moffat J., Grueneberg D.A., Yang X., et al. A lentiviral RNAi library for human and mouse genes applied to an arrayed viral high-content screen. Cell 124 (2006) 1283-1298
173. Lee M.L., Tomsu K., and Von Eschen K.B. Duration of survival for disseminated malignant melanoma: results of a meta-analysis. Melanoma Res 10 (2000) 81-92
174. Tarhini A.A., and Agarwala S.S. Novel agents in development for the treatment of melanoma. Expert Opin Invest Drugs 14 (2005) 885-892
175. Cerroni L., Soyer H.P., and Kerl H. bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopathol 17 (1995) 7-11
176. Morales-Ducret C.R., van de Rijn M., LeBrun D.P., and Smoller B.R. bcl-2 expression in primary malignancies of the skin. Arch Dermatol 131 (1995) 909-912
177. Jansen B., Schlagbauer-Wadl H., Brown B.D., et al. bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med 4 (1998) 232-234
178. Jansen B., Wacheck V., Heere-Ress E., et al. Chemosensitisation of malignant melanoma by BCL2 antisense therapy. Lancet 356 (2000) 1728-1733
179. Wilhelm S.M., Carter C., Tang L., et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004) 7099-7109
180. Davies H., Bignell G.R., Cox C., et al. Mutations of the BRAF gene in human cancer. Nature 417 (2002) 949-954
181. Karasarides M., Chiloeches A., Hayward R., et al. B-RAF is a therapeutic target in melanoma. Oncogene 23 (2004) 6292-6298
182. Sharma A., Trivedi N.R., Zimmerman M.A., Tuveson D.A., Smith C.D., and Robertson G.P. Mutant V599EB-Raf regulates growth and vascular development of malignant melanoma tumors. Cancer Res 65 (2005) 2412-2421
183. Dal Lago L., D'Hondt V., and Awada A. Selected combination therapy with sorafenib: a review of clinical data and perspectives in advanced solid tumors. Oncologist 13 (2008) 845-858
184. O'Day S.J., Hamid O., and Urba W.J. Targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4): a novel strategy for the treatment of melanoma and other malignancies. Cancer 110 (2007) 2614-2627
185. Waterhouse P., Penninger J.M., Timms E., et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270 (1995) 985-988
186. Tivol E.A., Borriello F., Schweitzer A.N., Lynch W.P., Bluestone J.A., and Sharpe A.H. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3 (1995) 541-547
187. Peggs K.S., Quezada S.A., Korman A.J., and Allison J.P. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 18 (2006) 206-213
188. Quirbt I., Verma S., Petrella T., Bak K., and Charette M. Temozolomide for the treatment of metastatic melanoma. Curr Oncol 14 (2007) 27-33
189. Ribas A., Hauschild A., Kefford R., et al. Phase III, open-label, randomized, comparative study of tremelimumab (CP-675,206) and chemotherapy (temozolomide [TMZ] or decarbazine [DTIC]) in patients with advanced melanoma. J Clin Oncol 26 (2008) Abstract LBA9011
190. Kirshner J.R., He S., Balasubramanyam V., et al. Elesclomol induces cancer cell apoptosis through oxidative stress. Mol Cancer Ther 7 (2008) 2319-2327
191. Berkenblit A., Eder Jr. J.P., Ryan D.P., et al. Phase I clinical trial of STA-4783 in combination with paclitaxel in patients with refractory solid tumors. Clin Cancer Res 13 (2007) 584-590
192. Gonzalez R., Lawson D.H., Weber R.W., et al. Phase II trial of elesclomol (formerly STA-4783) and paclitaxel in stage IV metastatic melanoma (MM): subgroup analysis by prior chemotherapy. J Clin Oncol 26 (2008) Abstract 9036